Travere Therapeutics (17R) Stock Statistics & Valuation Metrics

Travere Therapeutics has a market cap or net worth of CHF4.93B. The enterprise value is CHF5.44K.

Travere Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Travere Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -13.95%.

The current PE Ratio of Travere Therapeutics is ―. Travere Therapeutics’s PEG ratio is 0.79.

In the last 12 months, Travere Therapeutics had revenue of 490.73M and earned -25.55M in profits. Earnings per share was -0.56.

In the last 12 months, operating cash flow was 92.70M and capital expenditures -41.18M, giving a free cash flow of 51.52M billion.

Travere Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Travere Therapeutics upcoming earnings date is Oct 22, 2026, After Close (Confirmed).

Travere Therapeutics as a current ratio of 2.74, with Debt / Equity ratio of 2515.72%

In the past 12 months, Travere Therapeutics has paid 988.00K in taxes.

Travere Therapeutics EV to EBITDA ratio is 164.03, with an EV/FCF ratio of -178.89.

Travere Therapeutics has CHF489.18M in cash and marketable securities with CHF616.90M in debt, giving a net cash position of -CHF127.73M billion.

Gross margin is 94.41%, with operating margin of -12.80%, and net profit margin of -5.21%.

The average price target for Travere Therapeutics is CHF60.62, which is 11.43% higher than the current price. The consensus rating is Strong Buy